-47%

est. 2Y upside i

HealthcareSeries B

Modern, AI-powered clinical trial software platform.

Rank

#355

Sector

HealthTech, Software

Est. Liquidity

~4Y

Data Quality

Data: Medium

Curebase presents a strong upside opportunity driven by its high growth in the expanding decentralized clinical trials market and recent AI-powered platform enhancements.

Last updated: March 10, 2026

Bull (35%)+285%

Curebase successfully leverages its AI-powered eClinical platform and Sitebase offering to capture significant market share in the rapidly growing decentralized clinical trials (DCT) segment. Strategic partnerships expand its reach, driving revenue to $50M by 2028 and justifying a premium 15x multiple for a $750M valuation, leading to a 284.6% upside for common shareholders.

Base (45%)+97%

Curebase maintains strong growth, albeit moderating from its current rate, as it navigates competitive pressures and executes its pivot to software. Revenue reaches $32M by 2028, valued at a 12x multiple, resulting in a $384M valuation and a 96.9% upside for common shareholders.

Bear (20%)-80%

The pivot to software faces significant headwinds, with incumbents like Medidata and IQVIA expanding their DCT offerings, leading to slower growth and increased customer acquisition costs. Revenue stalls at $13.5M by 2028, and a lower 6.37x multiple results in an $86.2M valuation. Given the $59M liquidation preference, common shareholders experience an 80% loss.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

30%

Investors hold $59M in liquidation preferences, representing 30.3% of the current $195M valuation, which significantly impacts common stock value in lower exit scenarios.

Dilution Risk

moderate

As a Series B company, 1-2 additional funding rounds are likely before a liquidity event, leading to further dilution for existing shareholders.

Secondary Liquidity

none

There is currently no active secondary market or tender offer for Curebase shares, limiting liquidity for employees.

Questions to Ask at the Interview

Strategic questions based on Curebase's data — designed to show you've done your homework.

  • 1

    “Given the pivot from clinical operations to a pure software focus, how is Curebase ensuring its software remains deeply integrated with the operational realities of decentralized trials, especially against competitors like Medidata and Science 37 who have established service arms?”

  • 2

    “With a current revenue of ~$8M and a 350% YoY growth rate, what are the key strategies for scaling customer acquisition and retention over the next 24 months, particularly with the launch of new offerings like Sitebase?”

  • 3

    “Considering the $59M in total funding against the $195M valuation, how does Curebase plan to manage future dilution for employees, and what is the anticipated timeline and strategy for a liquidity event for common shareholders?”

Community

Valuation Sentiment

Our model estimates -47% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.